VRNA

Verona Pharma

58.75 USD
-1.51
2.51%
At close Feb 10, 4:00 PM EST
Pre-market
57.60
-1.15
1.96%
1 day
-2.51%
5 days
-0.91%
1 month
29.98%
3 months
47.35%
6 months
138.05%
Year to date
21.89%
1 year
241.57%
5 years
783.46%
10 years
335.19%
 

About: Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.

Employees: 79

0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

142% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 19

102% more capital invested

Capital invested by funds: $965M [Q2] → $1.94B (+$979M) [Q3]

57% more funds holding in top 10

Funds holding in top 10: 7 [Q2] → 11 (+4) [Q3]

21% more funds holding

Funds holding: 123 [Q2] → 149 (+26) [Q3]

0% less call options, than puts

Call options by funds: $27.5M | Put options by funds: $27.6M

0.73% less ownership

Funds ownership: 11.11% [Q2] → 10.38% (-0.73%) [Q3]

11% less repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 46

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$57
3%
downside
Avg. target
$65
10%
upside
High target
$74
26%
upside

4 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Raghuram Selvaraju
44% 1-year accuracy
144 / 330 met price target
2%upside
$60
Buy
Reiterated
21 Jan 2025
Roth MKM
Boobalan Pachaiyappan
63% 1-year accuracy
5 / 8 met price target
16%upside
$68
Buy
Initiated
10 Jan 2025
Wells Fargo
Tiago Fauth
57% 1-year accuracy
13 / 23 met price target
26%upside
$74
Overweight
Maintained
8 Jan 2025
Truist Securities
Joon Lee
53% 1-year accuracy
23 / 43 met price target
3%downside
$57
Buy
Reiterated
8 Jan 2025

Financial journalist opinion

Based on 3 articles about VRNA published over the past 30 days

Positive
Zacks Investment Research
2 weeks ago
Here's Why 'Trend' Investors Would Love Betting on Verona Pharma (VRNA)
Verona Pharma (VRNA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Here's Why 'Trend' Investors Would Love Betting on Verona Pharma (VRNA)
Positive
Investors Business Daily
3 weeks ago
Why Verona Pharma, A Triple-Digit Gainer In 2024, Surged Another 22% This Week
Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre. The post Why Verona Pharma, A Triple-Digit Gainer In 2024, Surged Another 22% This Week appeared first on Investor's Business Daily.
Why Verona Pharma, A Triple-Digit Gainer In 2024, Surged Another 22% This Week
Positive
Zacks Investment Research
3 weeks ago
Wall Street Analysts See a 30.65% Upside in Verona Pharma (VRNA): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 30.7% in Verona Pharma (VRNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts See a 30.65% Upside in Verona Pharma (VRNA): Can the Stock Really Move This High?
Positive
Zacks Investment Research
1 month ago
Verona Pharma (VRNA) Upgraded to Buy: What Does It Mean for the Stock?
Verona Pharma (VRNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Verona Pharma (VRNA) Upgraded to Buy: What Does It Mean for the Stock?
Positive
Zacks Investment Research
1 month ago
Verona Pharma (VRNA) is on the Move, Here's Why the Trend Could be Sustainable
If you are looking for stocks that are well positioned to maintain their recent uptrend, Verona Pharma (VRNA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Verona Pharma (VRNA) is on the Move, Here's Why the Trend Could be Sustainable
Positive
Seeking Alpha
1 month ago
Verona Pharma's Ohtuvayre Defies Expectations In Q4, But Stock Alpha May Now Be Limited
Verona Pharma's Ohtuvayre, a novel COPD treatment, achieved $36 million in Q4 sales, indicating strong market interest and unmet need for new therapies. Despite aggressive pricing, Ohtuvayre's broad label and significant prescriber uptake suggest potential for higher-than-expected peak annual sales. Verona Pharma holds $336 million in cash, projecting operational funding through at least the end of 2026.
Verona Pharma's Ohtuvayre Defies Expectations In Q4, But Stock Alpha May Now Be Limited
Neutral
GlobeNewsWire
1 month ago
Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights
Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectively
Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights
Neutral
GlobeNewsWire
2 months ago
Verona Pharma Announces December 2024 Investor Conference Participation
LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in December 2024:
Verona Pharma Announces December 2024 Investor Conference Participation
Positive
CNBC
3 months ago
Caligan picks up a stake in Verona Pharma, seeing an opportunity to generate more value
Verona Pharma has seen its share price skyrocket in anticipation of the commercial launch of its COPD treatment.
Caligan picks up a stake in Verona Pharma, seeing an opportunity to generate more value
Neutral
GlobeNewsWire
3 months ago
Verona Pharma to Present at Jefferies London Healthcare Conference
LONDON and RALEIGH, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 6:30 a.m. ET / 11:30 a.m. GMT.
Verona Pharma to Present at Jefferies London Healthcare Conference
Charts implemented using Lightweight Charts™